Abstract
Background: Serum adiponectin is a hormone of adipose tissue that activateslipid metabolism and exertsphysiological functions. Its level usually fluctuates in several metabolic diseases,including renal insufficiency and diabetes; it loses its protective role against diseases and becomes a potentially risk factor for erythroid abnormalities.
 Objectives: The study was designed to assess the association between adiponectin hormone, blood erythroid and various parameters in groups of patients.
 Method:The study included 130 patientsand 42 healthy subjects. Parameters of serum adiponectin, erythropoietin (EPO), red blood cells (RBC), hemoglobin (Hb), hematocrit (Hct), renal function, serum insulin, fasting blood sugar (FBS), glycated hemoglobin % (HbA1c%) and homeostatic model assessment of insulin resistance (HOMA-IR) were estimated in all groups.
 Result: Statistical analysis showed that high level of adiponectin was significantly associated with erythroid-related variables (EPO, RBC, Hb and Hct) in patients groups when compared with the control. Receiver Operating Characteristic (ROC) curve analysis showed that adiponectin is a significant risk factor for anemia progression in non-insulin dependent diabetes mellitus (NIDDM), end stage renal disease (ESRD)and diabetic nephropathy patients.
 Conclusion: We suggest that high serum adiponectin level is dependently associated with EPO level and erythroid abnormalities in NIDDM, kidney failure and diabetic nephropathy patients. The present findings regarding ROC curve analysis of adiponectin suggested that this hormone could represent a risk factor for erythroid abnormality in diabetic nephropathy at ESRD.
Highlights
Erythroid disorders, including anemia, are mostly encountered in the general clinical setting.Anemia is affected by hematopoietic growth factor erythropoietin (EPO)[1, 2]
A study by Mohammadet al.,[10]demonstrated that adiponectinexertsits effects on other organs via adiponectin receptors type I and II (AdipoR1 and AdipoR2), both have been identified in type 2 diabetes(NIDDM) and CKDpatients,which is consistent withthis study.The main causes for high adiponectin level in serum and urine in diabetic nephropathymay be either high biodegradation or elimination of adiponectin in the kidneys
Other causes might includeoverproduction of adiponectin in adipose tissue by amelioration of glomerular hypertrophy, through activation of adenosine 5'-monophosphate-activated protein kinase by AdipoR1 and activation of peroxisome proliferator-activated receptor (PPAR)-α signaling pathway by AdipoR2 (7)
Summary
Erythroid disorders, including anemia, are mostly encountered in the general clinical setting. Studies suggest that in patients with chronic renal failure,adiponectin is a predictor for progression of erythroid abnormalities and mortality [2, 5] This suggests that the biological protective effect of adiponectin against cardiovascular and metabolic diseases is decreased in uremic and diabetic patients [8]. The studied population included four group subjects: Group 1 (Control Group) included 40 healthy people (20 males and 22 females) whose mean age range was 62.60 ± 6.4 years They were selected based on a history of no arterial hypertensive, diabetic, cardiovascular, lung, renal, central nervous or endocrine system disorders. Group 4 (NIDDM+ESRD Patients group) included patients with diabetic nephropathyunder medical treatment and on HD (20 males and 20 females) with amean age range of 53.90 ± 4.75 years, as illustrated in Table-1.All patients and control groups were subjected to personal interviews through a specially designed questionnaire form. Serum fasting insulin was measured by ELISA Kit (Cell biolabs INC., 5064 San Diego, USA)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
